182 related articles for article (PubMed ID: 17121839)
1. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
Zhang J; Wang S; Kern S; Cui X; Danner RL
J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
[TBL] [Abstract][Full Text] [Related]
2. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
4. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
5. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
6. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
[TBL] [Abstract][Full Text] [Related]
7. cGMP-independent nitric oxide signaling and regulation of the cell cycle.
Cui X; Zhang J; Ma P; Myers DE; Goldberg IG; Sittler KJ; Barb JJ; Munson PJ; Cintron Adel P; McCoy JP; Wang S; Danner RL
BMC Genomics; 2005 Nov; 6():151. PubMed ID: 16269079
[TBL] [Abstract][Full Text] [Related]
8. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.
de Carné Trécesson S; Guillemin Y; Bélanger A; Bernard AC; Preisser L; Ravon E; Gamelin E; Juin P; Barré B; Coqueret O
J Biol Chem; 2011 Apr; 286(15):12825-38. PubMed ID: 21292770
[TBL] [Abstract][Full Text] [Related]
9. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1).
Zhu H; Chang BD; Uchiumi T; Roninson IB
Cell Cycle; 2002 Jan; 1(1):59-66. PubMed ID: 12429910
[TBL] [Abstract][Full Text] [Related]
10. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Facchinetti MM; De Siervi A; Toskos D; Senderowicz AM
Cancer Res; 2004 May; 64(10):3629-37. PubMed ID: 15150122
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein.
Fischer M; Quaas M; Wintsche A; Müller GA; Engeland K
Nucleic Acids Res; 2014 Jan; 42(1):163-80. PubMed ID: 24071582
[TBL] [Abstract][Full Text] [Related]
12. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1: target and regulator of transcriptional control.
Martin BT; Strebhardt K
Cell Cycle; 2006 Dec; 5(24):2881-5. PubMed ID: 17172872
[TBL] [Abstract][Full Text] [Related]
14. A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.
Akdeli N; Riemann K; Westphal J; Hess J; Siffert W; Bachmann HS
Mol Cancer; 2014 Apr; 13():87. PubMed ID: 24767679
[TBL] [Abstract][Full Text] [Related]
15. Molecular interactions of polo-like kinase 1 in human cancers.
Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
[TBL] [Abstract][Full Text] [Related]
16. Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1) transcription by Sp1 is mediated via distinct cis-acting positive and negative regulatory elements in the proximal p21(WAF1/Cip1) promoter.
Kavurma MM; Khachigian LM
J Cell Biochem; 2004 Nov; 93(5):904-16. PubMed ID: 15389873
[TBL] [Abstract][Full Text] [Related]
17. Plk1, a negative regulator of p21?
Liu X
Cell Cycle; 2009 Feb; 8(3):336-7. PubMed ID: 19164953
[No Abstract] [Full Text] [Related]
18. JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1.
Ramkumar P; Lee CM; Moradian A; Sweredoski MJ; Hess S; Sharrocks AD; Haines DS; Reddy EP
J Biol Chem; 2015 Dec; 290(49):29617-28. PubMed ID: 26468278
[TBL] [Abstract][Full Text] [Related]
19. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.
Salvatore G; Nappi TC; Salerno P; Jiang Y; Garbi C; Ugolini C; Miccoli P; Basolo F; Castellone MD; Cirafici AM; Melillo RM; Fusco A; Bittner ML; Santoro M
Cancer Res; 2007 Nov; 67(21):10148-58. PubMed ID: 17981789
[TBL] [Abstract][Full Text] [Related]
20. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.
Chiang WC; Teng CM; Lin SL; Chen YM; Tsai TJ; Hsieh BS
Eur J Pharmacol; 2005 Jul; 517(1-2):1-10. PubMed ID: 15950964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
